Gene Editing Companies Hit Back at Paper That Criticized CRISPR – MIT Technology Review
MIT Technology Review |
Gene Editing Companies Hit Back at Paper That Criticized CRISPR
MIT Technology Review The paper, titled “Unexpected mutations after CRISPR–Cas9 editing in vivo,” triggered a rash of negative headlines after claiming the gene-editing tool caused widespread and unpredictable havoc in the genomes of edited mice, introducing hundreds of … Editas Medicine: Addressing The Negatives -$0.41 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter |
